Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Treasury Shares (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Treasury Shares for 4 consecutive years, with $1.2 million as the latest value for Q4 2023.

  • On a quarterly basis, Treasury Shares fell 7.87% to $1.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $1.2 million, a 7.87% decrease, with the full-year FY2023 number at $1.2 million, down 7.87% from a year prior.
  • Treasury Shares was $979608.0 for Q3 2025 at Mereo BioPharma, roughly flat from $979608.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $979608.0 in Q1 2025 to a low of $855375.0 in Q1 2024.
  • A 3-year average of $918335.6 and a median of $923400.0 in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: fell 13.13% in 2022, then dropped 7.87% in 2023.
  • Mereo BioPharma's Treasury Shares stood at $1.7 million in 2020, then fell by 10.82% to $1.5 million in 2021, then fell by 13.13% to $1.3 million in 2022, then fell by 7.87% to $1.2 million in 2023.
  • Per Business Quant, the three most recent readings for MREO's Treasury Shares are $1.2 million (Q4 2023), $1.3 million (Q4 2022), and $1.5 million (Q4 2021).